Literature DB >> 17457930

Liver transplantation for status 1: the consequences of good intentions.

Sue V McDiarmid1, Nathan P Goodrich, Ann M Harper, Robert M Merion.   

Abstract

Status 1 is the listing category reserved for patients awaiting liver transplantation who are at risk of imminent death. This high allocation priority was intended to benefit patients with acute liver failure and children with severe chronic liver failure. However, the status 1 criteria were not well defined. The aims of this study, which used the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients database for patients wait-listed between February 27, 2002, and September 30, 2003, were to determine the indication and numbers of children and adults at status 1 (including regional variations); examine death rates on the waiting list for children at vs. not at status 1; and examine time to death, transplant, or removal from the waiting list for both pediatric and adult status 1 candidates. During the study period, 40.3% of children and 6.1% of adults were transplanted at status 1. The indication was acute liver failure in 52.1% of adults and 31% of children. Among status 1 transplants, Regional Review Board exceptions were granted for 16.7% of children and 10.1% of adults. Death rates for children listed at status 1 by exception per patient-year at risk were substantially lower (0.51) than those of children with acute liver failure (4.06) or with chronic liver disease and Pediatric End-Stage Liver Disease score > or =25 (4.63). The percentage of adults who died while on the waiting list within 90 days of listing was more than twice that of children, whereas the percentages transplanted were similar. Patients listed and transplanted at status 1 were a heterogeneous population with an overrepresentation of children with varying degrees of chronic liver disease and other exceptions, and an associated wide variation in waiting list mortality. Recent changes in status 1 criteria provide stricter definitions, particularly for children, including the removal of the "by exception" category, with the intent that all candidates listed at status 1 share a similar mortality risk.

Entities:  

Mesh:

Year:  2007        PMID: 17457930     DOI: 10.1002/lt.21125

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  School outcomes in children registered in the studies for pediatric liver transplant (SPLIT) consortium.

Authors:  Susan M Gilmour; Lisa G Sorensen; Ravinder Anand; Wanrong Yin; Estella M Alonso
Journal:  Liver Transpl       Date:  2010-09       Impact factor: 5.799

2.  Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years: Analysis of the UNOS Database.

Authors:  Noelle H Ebel; Evelyn K Hsu; Kristin Berry; Simon P Horslen; George N Ioannou
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

Review 3.  Acute liver failure including acetaminophen overdose.

Authors:  Robert J Fontana
Journal:  Med Clin North Am       Date:  2008-07       Impact factor: 5.456

4.  Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study.

Authors:  Robert J Fontana; Caitlyn Ellerbe; Valerie E Durkalski; Amol Rangnekar; Rajender K Reddy; Todd Stravitz; Brendan McGuire; Timothy Davern; Adrian Reuben; Iris Liou; Oren Fix; Daniel R Ganger; Raymond T Chung; Mike Schilsky; Steven Han; Linda S Hynan; Corron Sanders; William M Lee
Journal:  Liver Int       Date:  2014-07-28       Impact factor: 5.828

5.  Living Donor Liver Transplantation vs. Split Liver Transplantation Using Left Lateral Segment Grafts in Pediatric Recipients: An Analysis of the UNOS Database.

Authors:  Christina Dalzell; Paola A Vargas; Kyle Soltys; Frank Dipaola; George Mazariegos; Jose Oberholzer; Nicolas Goldaracena
Journal:  Transpl Int       Date:  2022-03-22       Impact factor: 3.782

6.  Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy.

Authors:  Samuel J I Blackford; Soon Seng Ng; Joe M Segal; Aileen J F King; Amazon L Austin; Deniz Kent; Jennifer Moore; Michael Sheldon; Dusko Ilic; Anil Dhawan; Ragai R Mitry; S Tamir Rashid
Journal:  Stem Cells Transl Med       Date:  2018-11-19       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.